Related Experiment Video
Updated: Aug 5, 2026
28:13
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Left Atrial Appendage Occlusion Versus Medical Therapy in Atrial Fibrillation: A Systematic Review and Meta-Analysis
Muhammad Aslam Khan1, Anza Muhammad2, Sheeza Nawaz1
1Department of Internal Medicine, Guthrie Clinic Robert Packer Hospital, Sayre, PA 18840, USA.
Journal of Clinical Medicine
|July 28, 2026
Summary
Percutaneous left atrial appendage occlusion (LAAO) shows no significant difference in stroke prevention compared to medical therapy for atrial fibrillation (AF). However, LAAO substantially reduces nonprocedural bleeding, making it a potential alternative for high-risk patients.
Area of Science:
- Cardiology and Interventional Cardiology
- Stroke Prevention Strategies
- Atrial Fibrillation Management
Background:
- Percutaneous left atrial appendage occlusion (LAAO) is a key nonpharmacologic stroke prevention method for atrial fibrillation (AF).
- Comparative effectiveness and safety of LAAO versus contemporary medical therapy, including direct oral anticoagulants (DOACs), require further clarification.
- Recent large randomized controlled trials (RCTs) provide new data for this comparison.
Purpose of the Study:
- To systematically review and meta-analyze RCTs comparing catheter-based LAAO with medical therapy in AF patients.
- To evaluate the comparative effectiveness and safety of LAAO against medical therapy for stroke prevention in AF.
Main Methods:
- Systematic review and meta-analysis of RCTs comparing LAAO with medical therapy in AF patients.
- Searched PubMed, CENTRAL, and ScienceDirect databases.
- Pooled dichotomous outcomes using risk ratios (RRs) with 95% confidence intervals (CIs) via random-effects models; assessed risk of bias using ROB 2.
Main Results:
- Six RCTs involving 7073 participants were analyzed.
- LAAO showed no significant differences in the composite endpoint, all-cause death, cardiovascular death, all stroke/TIA, or total major bleeding compared to medical therapy.
- LAAO significantly reduced nonprocedural bleeding (RR 0.54; 95% CI 0.46-0.63) but confidence intervals for ischemic stroke/TIA and systemic embolism remained wide.
Conclusions:
- No significant differences were found between LAAO and medical therapy for the composite endpoint, mortality, or most thromboembolic outcomes.
- LAAO demonstrated a significant reduction in nonprocedural bleeding, suggesting potential benefits for specific patient groups.
- LAAO may be considered an individualized alternative for selected AF patients with high bleeding risk or anticoagulation intolerance, despite residual uncertainty regarding rare thromboembolic events.
Related Concept Videos
01:26Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
01:25Mitral Regurgitation III: Medical Management
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
01:25Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
01:26Aneurysm III: Interprofessional Care
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:25Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...